Visus Therapeutics Revenue and Competitors

Location

$56M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Visus Therapeutics's estimated annual revenue is currently $3.7M per year.(i)
  • Visus Therapeutics's estimated revenue per employee is $77,500
  • Visus Therapeutics's total funding is $56M.

Employee Data

  • Visus Therapeutics has 48 Employees.(i)
  • Visus Therapeutics grew their employee count by 12% last year.

Visus Therapeutics's People

NameTitleEmail/Phone
1
CEO, Executive DirectorReveal Email/Phone
2
Chief Medical Officer and Head R&DReveal Email/Phone
3
VP, Human ResourcesReveal Email/Phone
4
VP, Pharmaceutical DevelopmentReveal Email/Phone
5
VP Information TechnologyReveal Email/Phone
6
VP MarketingReveal Email/Phone
7
VP Pharmaceutical DevelopmentReveal Email/Phone
8
VP, Clinical Operations and ComplianceReveal Email/Phone
9
Associate VP, Project & Portfolio ManagementReveal Email/Phone
10
VPReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.9M60%N/AN/A
#2
$0.9M60%N/AN/A
#3
$5.1M336%N/AN/A
#4
$5.7M3742%N/AN/A
#5
$1.4M18-10%N/AN/A
#6
$3.7M48-21%$16MN/A
#7
$1.1M70%N/AN/A
#8
$0.8M5-81%N/AN/A
#9
$2.5M16-27%N/AN/A
#10
$0.8M5-17%N/AN/A
Add Company

What Is Visus Therapeutics?

Visus Therapeutics is a clinical-stage pharmaceutical company focused on developing innovative ophthalmic therapies to improve vision for people around the world. With offices in Seattle, WA and Irvine, CA., our lead clinical candidate is BRIMOCHOL, an investigational drug designed to be a once-daily eye drop to correct for the loss of near vision associated with presbyopia. In parallel, Visus Therapeutics is focused on advancing its pipeline of early-stage ophthalmic product candidates with applications in ocular surface disease, glaucoma, and age-related macular degeneration.

keywords:N/A

$56M

Total Funding

48

Number of Employees

$3.7M

Revenue (est)

12%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Visus Therapeutics News

2022-03-22 - Clinical Catch-Up: Moderna COVID-19 Vaccine for Kids and ...

Visus Therapeutics launched the first of two pivotal Phase III Trials for Brimochol PF for presbyopia. Presbyopia is loss of near vision...

2022-03-22 - Visus Therapeutics kicks off Phase 3 pivotal trial for ...

Visus Therapeutics kicks off Phase 3 pivotal trial for presbyopia treatment ... The company has dosed the first patients in a Phase 3 trial...

2022-03-22 - Visus Therapeutics Initiates Phase 3 Pivotal Trials of ...

With offices in Seattle, Wash., and Irvine, Calif., Visus Therapeutics is a clinical-stage pharmaceutical company focused on developing...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$9.6M480%N/A
#2
$9.7M484%N/A
#3
$1.7M487%N/A
#4
$5.6M48N/AN/A
#5
$5.6M48N/AN/A